News2023-08-28T10:30:11-04:00

Penn State College of Medicine, Beat Childhood Cancer Research Consortium and Four Diamonds launch clinical trial that aims to combat solid tumors

In the press, News|

In a step toward fighting solid tumors in children and young adults, Penn State College of Medicine, the Beat Childhood Cancer Research Consortium and Four Diamonds, along with Senhwa Biosciences, Inc. are launching a pioneering clinical[...]

US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer

In the press, News|

LOUISVILLE, Ky.--(BUSINESS WIRE)--USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved IWILFIN™ (eflornithine) 192 mg tablets, a groundbreaking oral maintenance therapy for high-risk[...]

Endowment Gift Establishes Haworth Family Pediatric Oncology Innovative Therapeutics Clinic at Helen Devos Children’s Hospital

News|

Children fighting cancer have new hope thanks to an endowment gift from Dick and Ethie Haworth to the Helen DeVos Children’s Hospital Foundation. Their major gift establishes the Haworth Family[...]

Cover for Research: Beat Childhood Cancer
5,516

Research: Beat Childhood Cancer

The Beat Childhood Cancer Research Consortium is a group of 54+ universities and children's hospitals

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons
2 weeks ago
Research: Beat Childhood Cancer

Our team had the privilege of presenting three scientific posters and two oral presentations at #ASPHO2025.

Scroll to see the posters in action:
- Safety of Naxitamab + GM-CSF in Combination with Induction Chemotherapy in High-Risk Neuroblastoma
- Survival Outcomes in Patients with High-Risk Neuroblastoma in Remission 7 Years after Starting DFMO (IWILFIN®/Eflornithine) Maintenance Therapy
-Safety Comparison of Two Different Dosing Regimens for Oral Eflornithine in Pediatric Solid Tumors

The two oral presentations were:
- Dr. Sholler - Special Interest Group Physician Scientist "Investigational Trial to FDA Approval - DFMO Drug Development"
- Dr. Kraveka - "Educational Theater: FDA-Approved Anti-GD2 Cytotoxic Immunotherapy for High-Risk Neuroblastoma: Multi-center Efficacy and Safety Data Review"
... See MoreSee Less

Our team had the privilege of presenting three scientific posters and two oral presentations at #ASPHO2025.

Scroll to see the posters in action:
- Safety of Naxitamab + GM-CSF in Combination with Induction Chemotherapy in High-Risk Neuroblastoma
- Survival Outcomes in Patients with High-Risk Neuroblastoma in Remission 7 Years after Starting DFMO (IWILFIN®/Eflornithine) Maintenance Therapy
-Safety Comparison of Two Different Dosing Regimens for Oral Eflornithine in Pediatric Solid Tumors

The two oral presentations were:
- Dr. Sholler - Special Interest Group Physician Scientist Investigational Trial to FDA Approval - DFMO Drug Development
- Dr. Kraveka - Educational Theater: FDA-Approved Anti-GD2 Cytotoxic Immunotherapy for High-Risk Neuroblastoma: Multi-center Efficacy and Safety Data ReviewImage attachmentImage attachment+2Image attachment

ASPHO Exhibition 2025. We love connecting with our Pediatric Oncology community! ... See MoreSee Less

ASPHO Exhibition 2025. We love connecting with our Pediatric Oncology community!

See everyone at the American Society of Pediatric Hematology/Oncology (ASPHO) this Thursday-Friday! ... See MoreSee Less

See everyone at the American Society of Pediatric Hematology/Oncology (ASPHO) this Thursday-Friday!

Happy National Physicians week to all of the doctors in our BCC family! Their dedication, compassion and expertise make the world of difference for our patients 🌎 👧 💊

#PhysiciansWeek #principalinvestigators #pediatriccancer #beatchildhoodcancer
... See MoreSee Less

Happy National Physicians week to all of the doctors in our BCC family! Their dedication, compassion and expertise make the world of difference for our patients 🌎 👧 💊

#physiciansweek #principalinvestigators #pediatriccancer #beatchildhoodcancer

We are so lucky to have such an amazing team! 🍀 ... See MoreSee Less

We are so lucky to have such an amazing team! 🍀

... See MoreSee Less

Load more
Go to Top